• Robert D McBane, Charles L Loprinzi, Aneel Ashrani, Charles J Lenz, Damon Houghton, Tyler Zemla, Jennifer G Le-Rademacher, and Waldemar E Wysokinski.
• Vascular Medicine Division, Gonda Vascular Center, Mayo Clinic, Rochester, Minnesota.
• Eur. J. Haematol. 2020 Feb 1; 104 (2): 88-96.

BackgroundCancer-associated venous thromboembolism (VTE) carries a high rate of recurrence and death. Guidelines recommend continued anticoagulation therapy as long as active cancer persists. Apixaban 2.5 mg twice daily is the FDA-approved dose for secondary prevention regardless of VTE causation. Whether this apixaban dose is appropriate for secondary VTE prevention in cancer patients is not clear. The rationale and design of this investigator initiated phase III, multicenter, randomized, double-blind, trial assessing apixaban 2.5 mg vs 5 mg twice daily for 12 months for the secondary VTE prevention in cancer patients (n = 370) who have completed 6 months (but no more than 12 months) of anticoagulation is provided (NCT03080883).Methods/DesignThe primary study objective is to estimate differences in the combined rate of major plus clinically relevant non-major bleeding for apixaban 2.5 mg vs 5 mg twice daily. Secondary efficacy outcome is to assess rates of venous or arterial thromboembolism. Participating centers are chosen from the Academic and Community Cancer Research United (ACCRU) consortium.ConclusionWe anticipate these trial results to provide evidence supporting low-dose apixaban as a safe agent for secondary prevention of cancer-associated VTE for patients who have already completed 6-12 months of anticoagulation.© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

26 keywords...

hide…